Breaking News Instant updates and real-time market news.

DBVT

DBV Technologies

$14.12

-0.58 (-3.95%)

17:34
12/19/18
12/19
17:34
12/19/18
17:34

DBV drops 50% to $7.00 after withdrawing peanut allergy application

DBVT DBV Technologies
$14.12

-0.58 (-3.95%)

12/19/18
PIPR
12/19/18
NO CHANGE
PIPR
Overweight
Aimmune retains competitive edge over DBV Technologies, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond thinks the recent disclosure that DBV Technologies' (DBVT) Viaskin Peanut may be excluded from the PDUFA program would likely mean an extended FDA review time, which he said "bodes well" for competitor Aimmune (AIMT), which this morning announced the initiation of its Phase 3 POSEIDON trial assessing the efficacy of AR101 in peanut-allergic children. Given that he reads the trial start as a sign that the FDA remains comfortable with the safety profile of AR101, and his view on AR101's clinical profile, Raymond said he believes Aimmune "retains the competitive edge" over DBV. He keeps an Overweight rating on Aimmune shares.
09/13/18
STFL
09/13/18
INITIATION
Target $35
STFL
Buy
DBV Technologies initiated with a Buy at Stifel
Stifel analyst Derek Archila initiated DBV Technologies with a Buy rating and a price target of $35, saying the stock offers a "favorable" risk-reward over the next 12 months. Archila acknowledges investors' skepticism due to the Viaskin peanut missing its Phase 3 lower confidence level, but adds that his talks with regulatory experts suggest an over 50% probability that the Viaskin Biologic License Application will be accepted and yield an eventual approval.
08/20/18
JMPS
08/20/18
NO CHANGE
Target $30
JMPS
Outperform
DBV Viaskin Peanut BLA acceptance could be derisking event, says JMP Securities
After hosting meetings with Kevin Trapp, DBV Technologies' newly appointed Chief Commercial Officer, JMP Securities analyst Liisa Bayko noted the company is prepared to submit its BLA for Viaskin Peanut in October and she looks for acceptance 60 days later, which she said would be the first positive milestone for the company and could be a "meaningful derisking event." Viaskin Peanut is eligible for priority review and her expectation is that DBV will receive it, added Bayko, who reiterated her Outperform rating and $30 price target on the shares.
04/18/18
04/18/18
NO CHANGE
Target $37

Buy
Pediatric allergist sees both DBV, Aimmune winning approval, says Jefferies
Jefferies analyst Eun Yang hosted a discussion panel with a pediatric allergist who believes both both DBV Technologies' (DBVT) Viaskin Peanut and Aimmune's (AIMT) AR101 will be approved by the FDA. The allergist thinks Viaskin would be preferable due to its lower burden of monitoring and AR101 would be preferred due to its stronger efficacy, Yang tells investors in a research note. The doctor believes choice of treatment, if both are approved, will depend on a patients' goal of treatment and preference. Yang has a Buy rating on DBV Technologies with a $37 price target.

TODAY'S FREE FLY STORIES

SAP

SAP

$129.13

0.55 (0.43%)

05:38
10/21/19
10/21
05:38
10/21/19
05:38
Earnings
SAP reports Q3 non-IFRS EPS EUR 1.30 vs. EUR 1.14 last year »

Reports Q3 revenue EUR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 19

    Nov

DANOY

Danone

$0.00

(0.00%)

05:32
10/21/19
10/21
05:32
10/21/19
05:32
Downgrade
Danone rating change  »

Danone downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

JBAXY

Julius Baer

$0.00

(0.00%)

05:30
10/21/19
10/21
05:30
10/21/19
05:30
Downgrade
Julius Baer rating change  »

Julius Baer downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHR

Danaher

$138.08

0.31 (0.23%)

05:28
10/21/19
10/21
05:28
10/21/19
05:28
Hot Stocks
Danaher to sell certain businesses to Sartorius AG for $750M »

Danaher announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 07

    Nov

SAP

SAP

$129.13

0.55 (0.43%)

, MSFT

Microsoft

$137.34

-2.34 (-1.68%)

05:26
10/21/19
10/21
05:26
10/21/19
05:26
Hot Stocks
SAP enters go-to-market partnership with Microsoft »

SAP (SAP) and Microsoft…

SAP

SAP

$129.13

0.55 (0.43%)

MSFT

Microsoft

$137.34

-2.34 (-1.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 23

    Oct

  • 26

    Oct

  • 27

    Oct

  • 29

    Oct

  • 06

    Nov

  • 19

    Nov

  • 21

    Nov

ALSMY

Alstom

$0.00

(0.00%)

05:26
10/21/19
10/21
05:26
10/21/19
05:26
Downgrade
Alstom rating change  »

Alstom downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DANOY

Danone

$0.00

(0.00%)

05:25
10/21/19
10/21
05:25
10/21/19
05:25
Downgrade
Danone rating change  »

Danone downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

HON

Honeywell

$165.61

-1.87 (-1.12%)

05:24
10/21/19
10/21
05:24
10/21/19
05:24
Hot Stocks
Honeywell sees 7,600 new business jet deliveries over next decade »

The business jet industry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$344.09

-25.04 (-6.78%)

05:23
10/21/19
10/21
05:23
10/21/19
05:23
Downgrade
Boeing rating change  »

Boeing downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

IRT

Independence Realty Trust

$15.03

(0.00%)

05:22
10/21/19
10/21
05:22
10/21/19
05:22
Downgrade
Independence Realty Trust rating change  »

Independence Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

RHHBY

Roche

$0.00

(0.00%)

05:21
10/21/19
10/21
05:21
10/21/19
05:21
Hot Stocks
Genentech says Phase III IMbrave150 study met co-primary endpoints »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

  • 06

    Nov

  • 08

    Nov

  • 11

    Nov

  • 12

    Nov

  • 07

    Dec

PINS

Pinterest

$25.30

-0.7 (-2.69%)

05:21
10/21/19
10/21
05:21
10/21/19
05:21
Upgrade
Pinterest rating change  »

Pinterest upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 19

    Nov

COMM

CommScope

$11.56

-0.06 (-0.52%)

05:20
10/21/19
10/21
05:20
10/21/19
05:20
Upgrade
CommScope rating change  »

CommScope upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 07

    Nov

  • 09

    Dec

MFGP

Micro Focus

$15.13

0.56 (3.84%)

, OTEX

OpenText

$39.30

-1.545 (-3.78%)

05:18
10/21/19
10/21
05:18
10/21/19
05:18
Recommendations
Micro Focus, OpenText analyst commentary  »

Micro Focus could attract…

MFGP

Micro Focus

$15.13

0.56 (3.84%)

OTEX

OpenText

$39.30

-1.545 (-3.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 06

    Nov

  • 19

    Nov

MSFT

Microsoft

$137.34

-2.34 (-1.68%)

, CRM

Salesforce

$144.18

-1.995 (-1.36%)

05:15
10/21/19
10/21
05:15
10/21/19
05:15
Recommendations
Microsoft, Salesforce, Intuit, SailPoint, Zuora, Varonis analyst commentary  »

High growth software…

MSFT

Microsoft

$137.34

-2.34 (-1.68%)

CRM

Salesforce

$144.18

-1.995 (-1.36%)

INTU

Intuit

$262.54

-4.03 (-1.51%)

SAIL

SailPoint

$18.32

-0.34 (-1.82%)

ZUO

Zuora

$13.63

-0.5 (-3.54%)

VRNS

Varonis

$62.36

-1.56 (-2.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 26

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 19

    Nov

  • 21

    Nov

  • 16

    Dec

XLRN

Acceleron

$42.16

-1.02 (-2.36%)

05:09
10/21/19
10/21
05:09
10/21/19
05:09
Recommendations
Acceleron analyst commentary  »

Piper sees near-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 07

    Dec

  • 04

    Apr

TLSNF

Telia

$0.00

(0.00%)

05:04
10/21/19
10/21
05:04
10/21/19
05:04
Downgrade
Telia rating change  »

Telia downgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALRM

Alarm.com

$47.23

-0.5 (-1.05%)

05:01
10/21/19
10/21
05:01
10/21/19
05:01
Upgrade
Alarm.com rating change  »

Alarm.com upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 13

    Nov

  • 09

    Dec

SWAV

ShockWave Medical

$32.30

-0.29 (-0.89%)

04:59
10/21/19
10/21
04:59
10/21/19
04:59
Initiation
ShockWave Medical initiated  »

ShockWave Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

APLS

Apellis

$27.78

-0.03 (-0.11%)

04:55
10/21/19
10/21
04:55
10/21/19
04:55
Conference/Events
Apellis participates in a conference call with JPMorgan »

SMid Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Dec

FPRX

Five Prime

$3.98

-0.11 (-2.69%)

04:55
10/21/19
10/21
04:55
10/21/19
04:55
Conference/Events
Five Prime management to meet with Wedbush »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

ADAP

Adaptimmune

$0.96

-0.035 (-3.54%)

04:55
10/21/19
10/21
04:55
10/21/19
04:55
Conference/Events
Adaptimmune management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 23

    Oct

ALDR

Alder Biopharmaceuticals

$18.92

0.02 (0.11%)

04:55
10/21/19
10/21
04:55
10/21/19
04:55
Conference/Events
Alder Biopharmaceuticals management to meet with Mizuho »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 21

    Feb

04:55
10/21/19
10/21
04:55
10/21/19
04:55
General news
Breaking General news story  »

3-Month Bill Auction to…

04:55
10/21/19
10/21
04:55
10/21/19
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.